CHICAGO, August 23, 2026, 09:36 CDT Tempus AI (TEM) jumped 40% this week, lifting its market value by $3.7 billion, which is more than two times what the company spent on acquiring Personalis (PSNL).
- Tempus AI ended Friday at $72.69, up 39.5% for the week.
- The surge increased market value by about $3.7 billion.
- The increase is about 2.5 times greater than the proposed value of the Personalis transaction.
- The average analyst price target stands at $62.64, representing a 13.8% decline from Friday’s closing price.
Tempus AI, Inc. NASDAQ:TEM gained roughly $3.7 billion in market capitalization last week. Encouraging Phase 3 cancer vaccine data boosted confidence in its proposed acquisition of Personalis.
The share price increased from $52.10 on August 14 to $72.69 on Friday, marking a 39.5% gain for the week. On Friday, shares advanced 9.1% with trading volume at 15.9 million.
Valuation is now the main question for investors. Over the week, the market valued the target acquisition at almost two and a half times its enterprise value. This indicates that investors were factoring in wider oncology platform gains, beyond a single deal.
| Market-value bridge | Value | Basis |
|---|---|---|
| Tempus market value, August 21 | $13.12 billion | Reported market cap |
| Estimated market value, August 14 | $9.40 billion | $52.10 × 180.43 million shares |
| Increase in estimated value for the week | $3.72 billion | Reporter calculation, preliminary |
| Personalis enterprise value | $1.50 billion | Announced transaction |
| Value increase divided by deal value | 2.48× | Reporter calculation, preliminary |
Momentum was driven by Moderna, Inc. NASDAQ:MRNA and Merck & Co., Inc. NYSE:MRK, whose INTerpath-001 trial achieved its primary endpoint in Phase 3 for resected melanoma. Moderna described it as the first combination therapy to demonstrate a clinically meaningful benefit over pembrolizumab on its own. The preliminary announcement did not specify key efficacy data.
Personalis, Inc. NASDAQ:PSNL provides genomic sequencing services tailored for personalized treatment programs. In July, Tempus reached an agreement to acquire Personalis at $16.25 per share. The enterprise value disclosed was $1.5 billion.
| Stock | August 19 | August 20 | August 21 | Weekly change |
|---|---|---|---|---|
| Tempus AI NASDAQ:TEM | up 24.09% | rising 8.82% | adding 9.06% | rising 39.52% |
| Personalis NASDAQ:PSNL | up 13.66% | gained 6.77% | increased 8.89% | up 30.91% |
| Moderna NASDAQ:MRNA | up 176.97% | dropped 23.55% | higher by 8.86% | up 129.21% |
The agreement is still subject to conditions. Payment will be made in Tempus shares, allowing for cash to make up as much as 50%. The exchange rate is variable, capped at 0.3356. Completion is anticipated by late 2026 or early 2027.
Tempus joined the rally as operations strengthened. Revenue in the second quarter climbed 22% to $382.5 million. Adjusted EBITDA was $8.0 million, compared with a loss of $5.6 million in the prior year period.
| Operating metric | Q2 2026 | Change / comparison |
|---|---|---|
| Revenue | $382.5 million | 22% higher from a year earlier |
| Diagnostics revenue | $289.3 million | Up 20% |
| Data and Applications revenue | $93.2 million | Up 28% |
| Gross profit | $246.5 million | Risen 26% |
| GAAP net income | $5.6 million | Previous year: -$42.8 million |
| Adjusted EBITDA | $8.0 million | Previous year: -$5.6 million |
| 2026 revenue guidance | $1.595-$1.605 billion | Growth expected at about 25% |
Chief Executive Eric Lefkofsky said investment in AI fueled robust expansion in oncology diagnostics and data licensing. The company secured nearly $200 million in new Data and Applications licenses over the quarter.
The valuation offers minimal tolerance for underperformance. Tempus is trading at 9.16 times its trailing sales. Its enterprise value is roughly 8.6 times the midpoint of projected 2026 revenue.
| Valuation and risk metric | Latest value | Investor read-through |
|---|---|---|
| Market cap / 2026 guidance midpoint | 8.20× | Initial estimate |
| Enterprise value / guidance midpoint | 8.59× | Initial estimate |
| Trailing price / sales | 9.16× | Growth commanded a high multiple |
| Free cash flow, trailing 12 months | -$263.2 million | Ongoing negative cash flow |
| Short interest / float | 28.74% | Heightens effects of sharp moves |
| RSI | 75.09 | Momentum at overbought level |
Wall Street remains divided despite the prevailing Buy consensus. BTIG increased its price target to $80 on Thursday. However, the average target among 16 analysts stands at $62.64, suggesting a 13.8% drop from Friday’s closing price.
| Analyst / firm | Rating | Latest target | Implied move | Date |
|---|---|---|---|---|
| Mark Massaro / BTIG | Buy | $80 | +10.06% | August 20 |
| Casey Woodring / J.P. Morgan | Hold | $45 | -38.09% | August 5 |
| David Westenberg / Piper Sandler | Hold | $56 | -22.96% | August 4 |
| Yi Chen / H.C. Wainwright | Buy | $56 | -22.96% | August 3 |
| Subbu Nambi / Guggenheim | Buy | $65 | -10.58% | August 3 |
| 16-analyst consensus | Buy | $62.64 average | -13.83% | Current |
The rise was accompanied by insider sales. On August 18, Lefkofsky, Ryan Fukushima and Andrew Polovin made three transactions with a combined value of approximately $10.2 million. These disclosures were filed before the most pronounced part of the price movement.
Risks: Tempus’s revenue impact remains unquantified after the Phase 3 outcome. Personalis is still awaiting regulatory and shareholder consent. Elevated sales multiples, ongoing negative free cash flow, and significant short interest heighten the risk of a reversal.
U.S. markets will not trade on Sunday. Looking ahead to next week, investors are expected to monitor analyst target updates and comprehensive trial release details. A new Personalis proxy or regulatory submission may also alter the transaction calculations.
Related articles: NASDAQ:TEM
